Intuitive Surgical, Inc.

The provided document does not mention any current or future plans for fundraising through debt or equity. Key points related to finance include: - Cash and investments totaled $8 billion at quarter-end, down from $9 billion last quarter due to stock repurchases, acquisitions, and capital expenditures. - Stock repurchases of $1.1 billion occurred in the quarter. - Capital expenditures were $103 million. - No mention of new debt issuance or equity offerings. - Interest income decreased due to lower average cash balances after repurchases. - The company focuses on growth from innovation, procedural volume expansion, and product portfolio development rather than new fundraising. Overall, the company appears well-capitalized and makes no statements regarding seeking new debt or equity financing.

- Intuitive continues investments in organizational capabilities, clinical trials, and research to support international strategy and market access efforts. - Investment in supply chain and manufacturing to support broader availability of Force Feedback instrumentation, expected to increase over 2026 and beyond. - Ongoing development and investment in digital infrastructure and AI road map, including telesurgery, decision support, augmented dexterity, and automation. - Focused investment in new product and procedure launches, particularly Single Port (SP) platform, expanding customer base, and securing geographic clearances. - Select localized manufacturing initiatives are being considered in large international markets to enhance competitiveness. - Acquisition of distributors in Europe and joint ventures (e.g., in China) to strengthen global market presence. - Capital placements include 431 da Vinci systems in Q1 (232 da Vinci 5, 34 SP, 34 XiR) and 52 Ion systems, reflecting ongoing capital investment in product portfolio expansion and adoption.

- **Da Vinci Procedure Growth:** Updated 2026 forecast expects 13.5% to 15.5% growth in da Vinci procedures, slightly higher than the previous 13%-15% range. - **Primary Growth Drivers:** General surgery in the U.S. and procedures outside urology internationally remain key drivers. - **Global Expansion:** Continuing to grow outside the U.S., with strong performance in markets like India, Canada, U.K., Korea, and Taiwan; China remains challenging. - **SP Platform Growth:** Robust procedure growth at 68% globally in Q1, expanding in Korea, Europe, Japan, and Taiwan; new SP stapler launch expected to support further growth. - **Innovation-led Revenue Growth:** Revenue growth outpaces procedure growth due to accretive pricing and new products like da Vinci 5, SP stapler, and AI/digital capabilities. - **Capital Placements:** 17% increase in da Vinci system placements in Q1 with more upgrades to da Vinci 5. - **Procedure Sensitivity:** Some procedure areas (like bariatrics) impacted by pharmaceutical management trends (e.g., GLP-1s).

- Intuitive updated 2026 da Vinci procedure growth forecast to 13.5%-15.5% (up from prior 13%-15%). - Non-GAAP gross profit margin for 2026 expected between 67.5% and 68.5%, reflecting 100 basis points impact from tariffs and higher input costs. - Non-GAAP operating expense growth forecasted between 11% and 14%. - Non-GAAP other income expected between $315M and $335M, primarily from interest income. - Non-GAAP income tax rate expected between 22% and 23%. - Q1 non-GAAP net income was $901M ($2.50 EPS), up from $662M ($1.81 EPS) year-over-year. - Operational leverage and product cost reductions contributed to margin improvement. - Gross margin impacted moderately by macro factors like oil, memory chips, and tariffs. - Innovation and new product adoption (da Vinci 5, Ion) are key drivers of revenue growth beyond procedure growth.

The provided pages of the document do not explicitly mention current, expected orderbook, or pending orders in quantitative terms. However, relevant insights include: - Strong procedure growth and system placements indicate a healthy demand environment. - Distributor acquisitions in Europe and joint ventures (e.g., in China) suggest expanding order channels internationally. - Customer ordering patterns for international distributors can be lumpy, with some placing orders for several quarters in advance, indicating some backlog or pending orders. - Capital placement strong in Q1, benefiting partly from stocking orders. - The company maintains a localized market approach with investments calibrated to market potential. - Expectations of continued procedure growth (e.g., 13.5%-15.5% procedure growth forecast for 2026) support a healthy future order intake. - Product portfolio expansion (dV5, SP, Ion) and pricing strategies aim to support future order growth. No explicit numeric details on orderbook or pending orders are provided.